Figure 2

Frequency of intestinal MAP DNA detection in subgroups of UC patients (n = 49). Comparisons were made using Fisher's exact test. For visualization, the number of patients in each subgroup was converted to 100% and the percentage of MAP positive and negative patients in each subgroup is shown, respectively. UC patients treated with corticosteroids had a significantly higher frequency of MAP detection than UC patients receiving no corticosteroids (C) whereas the detection of MAP DNA was not altered between IBD patients with anti-inflammatory therapy (AIT) and those without (A). Frequency of MAP specific DNA was not changed between UC patients treated with 5-amino salicylic acid (5-ASA) and its derivatives (B) or immunomodulators (azathioprine and infliximab, D) compared to those without the respective agents.